| 15/10/26 | 07:00:08 | 15 Oct 2026 | | Issue of Equity, Director Dealing & Voting Rights | RNS |
| 09/10/26 | 07:00:02 | 9 Oct 2026 | | Preliminary Results | RNS |
| 02/10/26 | 07:00:03 | 2 Oct 2026 | | Notice of GM | RNS |
| 24/09/26 | 07:00:06 | 24 Sept 2026 | | Scancell completes up to US$25m in debt financing | RNS |
| 24/09/26 | 06:00:00 | 24 Sept 2026 | | Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development | GNW |
| 03/09/26 | 14:00:00 | 3 Sept 2026 | | Scancell to Present at the H.C. Wainwright Sept 26 | RNS |
| 03/09/26 | 13:24:00 | 3 Sept 2026 | | Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference | GNW |
| 19/08/26 | 07:00:03 | 19 Aug 2026 | | iSCIB1+ MHRA CTA Approval for Ph3 trial | RNS |
| 06/08/26 | 13:00:21 | 6 Aug 2026 | | Holding(s) in Company | RNS |
| 31/07/26 | 17:32:40 | 31 Jul 2026 | | Holding(s) in Company | RNS |
| 31/07/26 | 07:00:06 | 31 Jul 2026 | | Extension of Option Exercise Period | RNS |
| 28/07/26 | 15:40:16 | 28 Jul 2026 | | Holding(s) in Company | RNS |
| 27/07/26 | 07:00:09 | 27 Jul 2026 | | Result of Retail Offer and Total Voting Rights | RNS |
| 24/07/26 | 07:30:00 | 24 Jul 2026 | | Correction: Merger and Financing | RNS |
| 23/07/26 | 16:30:21 | 23 Jul 2026 | | Oversubscribed UK Placing | RNS |
| 23/07/26 | 11:11:00 | 23 Jul 2026 | | Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing | GNW |
| 23/07/26 | 08:05:45 | 23 Jul 2026 | | Merger and Financing | RNS |
| 23/07/26 | 08:04:46 | 23 Jul 2026 | | Launch of Retail Offer | RNS |
| 23/07/26 | 08:04:39 | 23 Jul 2026 | | Proposed UK Placing | RNS |
| 26/06/26 | 14:13:45 | 26 Jun 2026 | | Scancell: Response to Press Speculation | RNS |
| 28/04/26 | 07:00:11 | 28 Apr 2026 | | FDA Fast Track Designation for iSCIB1+ | RNS |
| 28/04/26 | 07:00:00 | 28 Apr 2026 | | Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study | GNW |
| 02/04/26 | 07:00:05 | 2 Apr 2026 | | Scancell announces CFO transition | RNS |
| 29/01/26 | 07:00:07 | 29 Jan 2026 | | Half-year Financial Report | RNS |
| 26/01/26 | 07:00:02 | 26 Jan 2026 | | FDA clearance of IND application for iSCIB1+ | RNS |
| 22/01/26 | 07:00:08 | 22 Jan 2026 | | Notice of Results | RNS |
| 09/12/25 | 07:00:05 | 9 Dec 2025 | | Continued improvement in PFS with iSCIB1+ | RNS |
| 07/11/25 | 07:00:04 | 7 Nov 2025 | | Research Update | RNS |
| 30/10/25 | 15:30:05 | 30 Oct 2025 | | Result of AGM | RNS |
| 03/10/25 | 07:00:13 | 3 Oct 2025 | | Notice of AGM | RNS |
| 16/09/25 | 07:00:14 | 16 Sept 2025 | | Director Dealing | RNS |
| 11/09/25 | 07:00:12 | 11 Sept 2025 | | Final Results | RNS |
| 04/09/25 | 07:00:18 | 4 Sept 2025 | | Notice of Results | RNS |
| 08/08/25 | 12:31:39 | 8 Aug 2025 | | Director Dealing | RNS |
| 04/08/25 | 10:23:05 | 4 Aug 2025 | | Director/PDMR Shareholding | RNS |
| 22/07/25 | 07:00:06 | 22 Jul 2025 | | Strong Phase 2 data on iSCIB1+ in Melanoma | RNS |
| 16/07/25 | 07:00:02 | 16 Jul 2025 | | Share Option Exercise | RNS |
| 25/06/25 | 07:00:06 | 25 Jun 2025 | | Scancell initiates new arm in SCOPE Phase 2 study | RNS |
| 21/05/25 | 07:00:10 | 21 May 2025 | | Director Dealing | RNS |
| 14/04/25 | 07:00:08 | 14 Apr 2025 | | Partnership with NHS Cancer Vaccine Launch Pad | RNS |
| 01/04/25 | 07:00:12 | 1 Apr 2025 | | Scancell to present at 2025 AACR Annual Meeting | RNS |
| 20/02/25 | 07:00:09 | 20 Feb 2025 | | Issue of share options | RNS |
| 17/02/25 | 07:00:05 | 17 Feb 2025 | | Scancell presenting at AACR IO conference | RNS |
| 30/01/25 | 07:00:06 | 30 Jan 2025 | | Interim Results | RNS |
| 23/01/25 | 07:00:09 | 23 Jan 2025 | | Notice of Interim Results | RNS |
| 09/01/25 | 07:00:04 | 9 Jan 2025 | | Modi-1 Vaccine Achieves Early Clinical Validation | RNS |
| 09/12/24 | 11:41:51 | 9 Dec 2024 | | Result of Retail Offer and Total Voting Rights | RNS |
| 05/12/24 | 12:39:40 | 5 Dec 2024 | | Result of Placing and Subscription | RNS |
| 04/12/24 | 18:03:05 | 4 Dec 2024 | | Retail Offer for up to £1 million | RNS |
| 04/12/24 | 17:59:08 | 4 Dec 2024 | | Proposed fundraise in excess of £8.5 million | RNS |
